Amber Therapeutics raises $100M in a series A funding round to develop bio e-stim for urinary incontinence therapy

Jun 11, 2024•over 1 year ago

Amount Raised

$100 Million

LondonTherapeuticsBiotechnologyHealth Care

Description

Amber Therapeutics Ltd. has raised $100 million in a series A funding round to further develop its implantable closed-loop bioelectrical therapy to treat women suffering from mixed urinary incontinence. The financing is one of the largest series A rounds ever seen in Europe’s medical technology space.

Company Information

Company

Amber Therapeutics

Location

London, England, United Kingdom

About

Amber Therapeutics was founded in 2021 with a mission to develop and deliver breakthrough neuromodulation therapies that can fundamentally transform outcomes in areas of unmet clinical need. We have since grown into a multidisciplinary team, combining deep medical device experience with a culture and mindset focused on transformational innovation. Amber UI is the company’s first therapy, aiming to restore normal physiological function in women suffering with mixed urinary incontinence.

Related People

2 contacts

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Amber Therapeutics raises $100M in a series A funding round to develop bio e-stim for urinary incontinence therapy

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information